Analysis of the ingredients and mechanism of action of each ingredient in Jisandai (Epclusa)

Epclusa (Epclusa) is a broad-spectrum antiviral oral preparation mainly used to treat chronic hepatitis C virus (HCV) infection. It is a direct antiviral drug (DAA, Direct-Acting Antiviral () combination therapy consists of two active ingredients: Sofosbuvir (Sofosbuvir) and Velpatasvir (Velpatasvir). Through synergistic effect, it can achieve efficient suppression of multiple types of HCV, thereby achieving the goal of cure.

Sofosbuvir is one of the core components of Epclusa and is a nucleotide-type HCV NS5B polymerase inhibitor. It simulates natural nucleotides and is incorporated into the viral RNA replication chain, causing the RNA chain to terminate prematurely, thereby inhibiting viral replication. Sofosbuvir is metabolically activated into the triphosphate form in the body, and acts efficiently and specifically on NS5B polymerase, making it almost impossible for HCV replication to continue, which is the basis of the antiviral effect of Epclusa.

Velpatasvir is another key ingredient and is an NS5A inhibitor. NS5A is a multifunctional non-structural protein that participates in the formation of viral replication complexes and virus particle assembly. Velpatasvir blocks the formation of viral replication complexes and inhibits virus particle assembly and release by binding with high affinity to the NS5A protein. Because NS5Ais highly conserved in multiple HCVgenotypes, velpatasvir can provide broad-spectrum antiviral effects, thereby enhancing the drug's ability to cover different HCVgenotypes.

The combination of the two ingredients makesEpclusa a first-line all-genotypeHCV treatment. Sofosbuvir is responsible for directly inhibiting virus replication, while velpatasvir blocks virus assembly and release from another pathway, forming a dual inhibition mechanism and significantly improving the virus clearance rate (SVR, Sustained Virologic Response). also,Epclusa’s combination regimen can shorten the treatment course, reduce the risk of drug resistance, and is well tolerated in most patients, providing a safe and efficient cure option for HCV patients around the world.

Reference materials:https://www.drugs.com/